Update on Biomarkers of Hepatocellular Carcinoma

Roongruedee Chaiteerakij, Benyam D. Addissie, Lewis Rowland Roberts

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

New biomarkers of hepatocellular carcinoma (HCC) have been identified using advanced genomic, proteomic, and metabolomics technologies. These are being developed not only for use in diagnosis of HCC, but also in prediction of patient and treatment outcomes and individualization of therapy. Some HCC biomarkers are currently used in surveillance to detect early stage HCCs and reduce mortality. Further studies are needed to determine whether the recently identified HCC biomarkers can be used in clinical practice; most are only in phase 1 or 2 studies. The diagnostic and predictive abilities of biomarkers are limited by the heterogeneous nature of HCCs; there is no perfect single biomarker of this tumor. To improve performance, combinations of biomarkers (panels), or combinations of biomarkers and clinical parameters or laboratory test results, might be required. We describe recently discovered biomarkers of HCC and discuss challenges to their development and application.

Original languageEnglish (US)
Pages (from-to)237-245
Number of pages9
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Hepatocellular Carcinoma
Biomarkers
Metabolomics
Tumor Biomarkers
Proteomics
Technology
Mortality

Keywords

  • Early detection
  • Liver cancer
  • Prognosis
  • Prognostic factor
  • Tumor
  • α-Fetoprotein

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Update on Biomarkers of Hepatocellular Carcinoma. / Chaiteerakij, Roongruedee; Addissie, Benyam D.; Roberts, Lewis Rowland.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 2, 2015, p. 237-245.

Research output: Contribution to journalArticle

Chaiteerakij, Roongruedee ; Addissie, Benyam D. ; Roberts, Lewis Rowland. / Update on Biomarkers of Hepatocellular Carcinoma. In: Clinical Gastroenterology and Hepatology. 2015 ; Vol. 13, No. 2. pp. 237-245.
@article{0e06531a6ad240a6b3983994203fd5ca,
title = "Update on Biomarkers of Hepatocellular Carcinoma",
abstract = "New biomarkers of hepatocellular carcinoma (HCC) have been identified using advanced genomic, proteomic, and metabolomics technologies. These are being developed not only for use in diagnosis of HCC, but also in prediction of patient and treatment outcomes and individualization of therapy. Some HCC biomarkers are currently used in surveillance to detect early stage HCCs and reduce mortality. Further studies are needed to determine whether the recently identified HCC biomarkers can be used in clinical practice; most are only in phase 1 or 2 studies. The diagnostic and predictive abilities of biomarkers are limited by the heterogeneous nature of HCCs; there is no perfect single biomarker of this tumor. To improve performance, combinations of biomarkers (panels), or combinations of biomarkers and clinical parameters or laboratory test results, might be required. We describe recently discovered biomarkers of HCC and discuss challenges to their development and application.",
keywords = "Early detection, Liver cancer, Prognosis, Prognostic factor, Tumor, α-Fetoprotein",
author = "Roongruedee Chaiteerakij and Addissie, {Benyam D.} and Roberts, {Lewis Rowland}",
year = "2015",
doi = "10.1016/j.cgh.2013.10.038",
language = "English (US)",
volume = "13",
pages = "237--245",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Update on Biomarkers of Hepatocellular Carcinoma

AU - Chaiteerakij, Roongruedee

AU - Addissie, Benyam D.

AU - Roberts, Lewis Rowland

PY - 2015

Y1 - 2015

N2 - New biomarkers of hepatocellular carcinoma (HCC) have been identified using advanced genomic, proteomic, and metabolomics technologies. These are being developed not only for use in diagnosis of HCC, but also in prediction of patient and treatment outcomes and individualization of therapy. Some HCC biomarkers are currently used in surveillance to detect early stage HCCs and reduce mortality. Further studies are needed to determine whether the recently identified HCC biomarkers can be used in clinical practice; most are only in phase 1 or 2 studies. The diagnostic and predictive abilities of biomarkers are limited by the heterogeneous nature of HCCs; there is no perfect single biomarker of this tumor. To improve performance, combinations of biomarkers (panels), or combinations of biomarkers and clinical parameters or laboratory test results, might be required. We describe recently discovered biomarkers of HCC and discuss challenges to their development and application.

AB - New biomarkers of hepatocellular carcinoma (HCC) have been identified using advanced genomic, proteomic, and metabolomics technologies. These are being developed not only for use in diagnosis of HCC, but also in prediction of patient and treatment outcomes and individualization of therapy. Some HCC biomarkers are currently used in surveillance to detect early stage HCCs and reduce mortality. Further studies are needed to determine whether the recently identified HCC biomarkers can be used in clinical practice; most are only in phase 1 or 2 studies. The diagnostic and predictive abilities of biomarkers are limited by the heterogeneous nature of HCCs; there is no perfect single biomarker of this tumor. To improve performance, combinations of biomarkers (panels), or combinations of biomarkers and clinical parameters or laboratory test results, might be required. We describe recently discovered biomarkers of HCC and discuss challenges to their development and application.

KW - Early detection

KW - Liver cancer

KW - Prognosis

KW - Prognostic factor

KW - Tumor

KW - α-Fetoprotein

UR - http://www.scopus.com/inward/record.url?scp=84927695900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927695900&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2013.10.038

DO - 10.1016/j.cgh.2013.10.038

M3 - Article

VL - 13

SP - 237

EP - 245

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -